READ THIS NEXT: This Common Daily Medication May Become Harder to Find, Makers Say. Over the summer, several medications were pulled from shelves, including morphine tablets manufactured by Bryant Ranch Prepack Inc. According to the June 29 recall announcement from the FDA, the tablets were pulled due to an issue with the labels. Morphine Sulfate 30 mg Extended Release tablets were mislabeled as 60-mg tablets, and the Morphine Sulfate 60 mg Extended Release tablets were mislabeled as 30 mg. As a result of the mixup, patients prescribed the 30 mg dose could mistakenly take the 60-mg tablets and put themselves at risk for overdose and death. And those prescribed 60-mg tablets who take 30-mg tablets could be at risk of withdrawal, as well as untreated pain, the FDA warned. Patients with the medication were asked to stop using it immediately and to contact the manufacturer. In July, patients with diabetes dealt with a significant recall, when one batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100) was voluntarily recalled by Mylan Pharmaceuticals Inc. This was again due to a labeling issue, according to the FDA announcement, as some insulin pens were found to be missing labels. Patients could experience “serious complications” if products were mixed up with different types of insulin, and they were instructed to call recall management firm Sedgwick. But the most recent recall isn’t the result of labeling issues—it’s actually due to potential contamination. On Sept. 26, the FDA announced that Eugia US LLC (formerly AuroMedics Pharma LLC), a company based in East Windsor, New Jersey, issued a voluntary recall of one lot of AuroMedics Acyclovir Sodium Injection 500 mg per 10 mL (50 mg/mL), 10 mL single dose vial. The medication is known by the brand name Zovirax.ae0fcc31ae342fd3a1346ebb1f342fcb The medication contains acyclovir, which is a treatment used for herpes viruses, the FDA stated. The injection is used to treat “initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2)” in patients who are immunocompromised, as well as “initial clinical episodes of herpes genitalis in immuno-competent patients,” meaning those who have a normal immune response. Cutaneous herpes simplex can cause lesions on the skin, while mucosal herpes simplex affects mucosa, which is the “soft tissue that lines the body’s canals and organs,” according to the Cleveland Clinic. RELATED: For more up-to-date information, sign up for our daily newsletter. According to the FDA announcement, the recall affects lot number AC22006, which has an expiration date of Aug. 2023. Products were shipped to wholesalers across the country between June 8 and June 13, packaged in glass vials, and labeled with the National Drug Code (NDC) 55150-154-10. The vials are being recalled following a “product complaint,” which noted “the presence of dark red, brown and black particulate inside the vial.” Eugia US LLC hasn’t received any reports of adverse events related to the recalled lot. However, products that contain these particulates could lead to “inflammation, allergic reactions, or circulatory system complications” that could become life-threatening, the FDA notes. If you have a recalled product in your medicine cabinet—and especially if you experience any health issues related to the product—the FDA asks that you call your doctor. Consumers should also call Qualanex (which provides support services for Eugia) at 1-888-280-2046 between 7 a.m. and 4 p.m. Central Standard Time, Monday through Friday, or email the company at [email protected] According to the recall announcement, Eugia US LLC is sending recall letters to those who received the product, arranging the return and replacement. Wholesalers and healthcare professionals are asked to put the recalled lot on hold immediately and contact Qualanex. Consumers can report quality problems and adverse reactions to the FDA’s MedWatch Adverse Event Reporting program online, or by regular mail or fax.
